161 related articles for article (PubMed ID: 26328493)
1. Radioiodinated Peptidic Imaging Probes for in Vivo Detection of Membrane Type-1 Matrix Metalloproteinase in Cancers.
Kondo N; Temma T; Shimizu Y; Ono M; Saji H
Biol Pharm Bull; 2015; 38(9):1375-82. PubMed ID: 26328493
[TBL] [Abstract][Full Text] [Related]
2. Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers.
Kondo N; Temma T; Shimizu Y; Watanabe H; Higano K; Takagi Y; Ono M; Saji H
Cancer Sci; 2013 Apr; 104(4):495-501. PubMed ID: 23305265
[TBL] [Abstract][Full Text] [Related]
3. Development of PEGylated peptide probes conjugated with (18)F-labeled BODIPY for PET/optical imaging of MT1-MMP activity.
Kondo N; Temma T; Deguchi J; Sano K; Ono M; Saji H
J Control Release; 2015 Dec; 220(Pt A):476-483. PubMed ID: 26578437
[TBL] [Abstract][Full Text] [Related]
4. Development of membrane type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant tumor detection.
Shimizu Y; Temma T; Sano K; Ono M; Saji H
Cancer Sci; 2011 Oct; 102(10):1897-903. PubMed ID: 21718387
[TBL] [Abstract][Full Text] [Related]
5. MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management.
Morcillo MÁ; García de Lucas Á; Oteo M; Romero E; Magro N; Ibáñez M; Martínez A; Garaulet G; Arroyo AG; López-Casas PP; Hidalgo M; Mulero F; Martínez-Torrecuadrada J
Contrast Media Mol Imaging; 2018; 2018():8382148. PubMed ID: 30224904
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunodetection of membrane type-1 matrix metalloproteinase relevant to tumor malignancy with a pre-targeting method.
Sano K; Temma T; Kuge Y; Kudo T; Kamihashi J; Zhao S; Saji H
Biol Pharm Bull; 2010; 33(9):1589-95. PubMed ID: 20823579
[TBL] [Abstract][Full Text] [Related]
7. Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas.
de Lucas AG; Schuhmacher AJ; Oteo M; Romero E; Cámara JA; de Martino A; Arroyo AG; Morcillo MÁ; Squatrito M; Martinez-Torrecuadrada JL; Mulero F
PLoS One; 2016; 11(7):e0158634. PubMed ID: 27462980
[TBL] [Abstract][Full Text] [Related]
8. Development of a Radiolabeled Peptide-Based Probe Targeting MT1-MMP for Breast Cancer Detection.
Min K; Ji B; Zhao M; Ji T; Chen B; Fang X; Ma Q
PLoS One; 2015; 10(10):e0139471. PubMed ID: 26437463
[TBL] [Abstract][Full Text] [Related]
9. Development of Radiolabeled Membrane Type-1 Matrix Metalloproteinase Activatable Cell Penetrating Peptide Imaging Probes.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
Molecules; 2015 Jul; 20(7):12076-92. PubMed ID: 26147581
[TBL] [Abstract][Full Text] [Related]
10. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors.
Temma T; Sano K; Kuge Y; Kamihashi J; Takai N; Ogawa Y; Saji H
Biol Pharm Bull; 2009 Jul; 32(7):1272-7. PubMed ID: 19571397
[TBL] [Abstract][Full Text] [Related]
11. Screening, Identification, and Characterization of an Affinity Peptide Specific to MT1-MMP and Its Application in Tumor Imaging.
Li X; Ma Z; Wang H; Ren L; Zhang D; Liang W; Zhang G; Zhang J; Yu D; Fang X
Bioconjug Chem; 2019 May; 30(5):1507-1517. PubMed ID: 30986050
[TBL] [Abstract][Full Text] [Related]
12. High-affinity peptide against MT1-MMP for in vivo tumor imaging.
Zhu L; Wang H; Wang L; Wang Y; Jiang K; Li C; Ma Q; Gao S; Wang L; Li W; Cai M; Wang H; Niu G; Lee S; Yang W; Fang X; Chen X
J Control Release; 2011 Mar; 150(3):248-55. PubMed ID: 21295090
[TBL] [Abstract][Full Text] [Related]
13. MT1-MMP activatable fluorogenic probes with enhanced specificity via high-affinity peptide conjugation for tumor imaging.
Ji X; Xie S; Jiao Y; Zhang X; Sun D; Yang VC; Wang M; He H; Sun L
Biomater Sci; 2020 Apr; 8(8):2308-2317. PubMed ID: 32186291
[TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe.
Shimizu Y; Temma T; Hara I; Makino A; Kondo N; Ozeki E; Ono M; Saji H
Cancer Sci; 2014 Aug; 105(8):1056-62. PubMed ID: 24863849
[TBL] [Abstract][Full Text] [Related]
15. A novel strategy to tag matrix metalloproteinases-positive cells for in vivo imaging of invasive and metastatic activity of tumor cells.
Zhao T; Harada H; Teramura Y; Tanaka S; Itasaka S; Morinibu A; Shinomiya K; Zhu Y; Hanaoka H; Iwata H; Saji H; Hiraoka M
J Control Release; 2010 May; 144(1):109-14. PubMed ID: 20096316
[TBL] [Abstract][Full Text] [Related]
16. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
17. In vivo biodistribution of radiolabeled MMP-2/9 activatable cell-penetrating peptide probes in tumor-bearing mice.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
Contrast Media Mol Imaging; 2015; 10(1):59-66. PubMed ID: 24823643
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
J Nucl Med; 2011 Feb; 52(2):279-86. PubMed ID: 21233187
[TBL] [Abstract][Full Text] [Related]
19. Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agent.
Van Steenkiste M; Oltenfreiter R; Frankenne F; Vervoort L; Maquoi E; Noel A; Foidart JM; Van De Wiele C; De Vos F
Cancer Biother Radiopharm; 2010 Oct; 25(5):511-20. PubMed ID: 20854210
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the MT1-MMP expression level of different cell lines by the naked eye.
Zhang X; Yuan Q; Gao X
Sci China Life Sci; 2018 Apr; 61(4):492-500. PubMed ID: 29556904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
